Booster HPV vaccine for recurrent respiratory papillomatosis
Treatments studied
Part of Ear, nose & throat, Infections clinical trials.
This study tests whether an extra dose of the Gardasil-9 vaccine can help reduce the number of surgeries needed for recurrent respiratory papillomatosis (RRP), a condition where non-cancerous growths recur in the airway. You may be eligible if you've had the vaccine before and still have frequent recurrences.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have recurrent respiratory papillomatosis (RRP), a condition with recurring growths in the airway.
- You completed a 2- or 3-dose series of Gardasil-9 more than 2 years ago.
- You have had at least 2 surgeries or other treatments for RRP since your vaccine series, and you still have recurrences.
- You have not had an allergic reaction to a previous Gardasil vaccine, and you do not have any active HPV-related cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two drugs, bevacizumab and PRGN-2012, to treat recurrent respiratory papillomatosis (RRP), a condition where non-cancerous growths come back in the airway. The goal is to see if the combination reduces the need for surgeries or other procedures.
This Phase 1 trial is testing a vaccine made from your own immune cells (dendritic cells) that may help your body fight the virus causing recurrent papillomas in your voice box. It is for people whose papillomas are caused by HPV type 6, who have had at least one recurrence in the past year.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
This study tests whether a single dose of the HPV vaccine is enough to protect against the viruses that cause several cancers. You will have the vaccine and some small tissue samples taken to see how your immune system responds.
This trial tests whether an HPV vaccine (Gardasil 9) can help women over 45 who still have HPV after treatment for a high-grade cervical lesion. It compares vaccinated and unvaccinated patients to see if vaccination lowers the risk of the lesion coming back.
Hear when a new Recurrent Respiratory Papillomatosis (RRP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.